CICC Starts Jiangsu Sinopep-Allsino Biopharmaceutical at Outperform With 88 Yuan Price Target
Nootech Biotech (688076): Deep-cultivating peptides to take advantage
Nootech Biotech (688076): Deeply involved in the peptide industry for many years, ushered in a harvest period, accelerated development under GLP-1 catalysis
Nootech Biotech (688076): The GLP-1 industry chain took the lead in benefiting from several tons of production capacity to help it take off
Nootech Biotech (688076): 2024 semi-annual results forecast released, profits continue to explode, surpassing market expectations
Nootech Biotech (688076): Self-selected products continue to be released, 24H1 performance grows rapidly
Nootech Biotech (688076): Performance exceeds expectations, continues to achieve advantages in the field of peptides, and the trend of high growth continues
Research reports unearthed | GF Securities: Maintain a “buy” rating for Notai Biotechnology, with obvious platform advantages and performance entering the redemption period.
Nootai Biotech (688076) 2024 semi-annual performance forecast review: Profit growth far exceeds expectations, leading peptide APIs are being released rapidly
Nootech Biotech (688076): Forward-looking layout, first-mover advantage, long-term growth space can be expected
Nootech Biotech (688076): The industry ushered in the growth of leading edge peptide APIs
Nootai Biotech (688076) Quarterly Report Review: Revenue exceeds market expectations, independent product release drives performance growth, peptide business flexibility is high
Nootech Biotech (688076): Self-selected products are growing rapidly, 2024Q1 performance growth is in line with expectations
Minsheng Securities released a research report on April 23 stating that it gave Nootai Biotech (688076.SH) a recommended rating. The main reasons for the rating include: 1) independent business selection supports rapid growth in performance, and the matri
Nootech Biotech (688076): High growth continues to improve profitability
Zhongtai Securities released a research report on April 23 stating that it maintains the purchase rating of Nootech Biotech (688076.SH). The main reasons for the rating include: 1) performance is higher than the median forecast, and advantages in the pept
Nootech Biotech (688076): Q1 is higher than the forecast median value in the field of polypeptides, continues to deliver, and is expected to continue to maintain a high growth trend
Nootech Biotech (688076): Leading companies on the peptide circuit have strong downstream demand and broad room for growth
Open Source Securities released a research report on April 15 stating that it gave Nootai Biotech (688076.SH) a purchase rating. The main reasons for the rating include: 1) leading peptide racetrack companies with a full industrial chain layout, opening u
Nootech Biotech (688076): Independent product release is optimistic that high growth will continue
No Data